Marcus Lind

Summary

Country: Sweden

Publications

  1. doi request reprint Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation
    Marcus Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Thromb Res 129:32-5. 2012
  2. doi request reprint The effect of insulin lispro on glycemic control in a large patient cohort
    Marcus Lind
    Department of Medicine, Uddevalla Hospital, Sweden
    Diabetes Technol Ther 11:51-6. 2009
  3. ncbi request reprint Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK
    Marcus Lind
    Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Diabetologia 57:1586-94. 2014
  4. doi request reprint Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study
    M Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Diabetologia 56:2601-8. 2013
  5. doi request reprint Incretin therapy and its effect on body weight in patients with diabetes
    Marcus Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Prim Care Diabetes 6:187-91. 2012
  6. doi request reprint The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes
    M Lind
    Department of Medicine, Uddevalla Hospital, 451 80 Uddevalla, Sweden
    Diabetologia 55:2946-53. 2012
  7. doi request reprint The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes
    Marcus Lind
    Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Prim Care Diabetes 6:53-9. 2012
  8. doi request reprint Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
    Marcus Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Prim Care Diabetes 6:41-6. 2012
  9. pmc The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables
    Marcus Lind
    Department of Medicine, Uddevalla Hospital, Uddevalla, Sweden
    PLoS ONE 4:e4412. 2009
  10. doi request reprint The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects
    M Lind
    Department of Medicine, NU Hospital Organization, SE 451 80 Uddevalla, Sweden
    Diabetologia 53:1093-8. 2010

Detail Information

Publications17

  1. doi request reprint Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation
    Marcus Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Thromb Res 129:32-5. 2012
    ..0-3.0. Our aim was to study whether INR variability, as assessed by the standard deviation of transformed INR (SDT(INR)) is more prognostically important than the TTR...
  2. doi request reprint The effect of insulin lispro on glycemic control in a large patient cohort
    Marcus Lind
    Department of Medicine, Uddevalla Hospital, Sweden
    Diabetes Technol Ther 11:51-6. 2009
    ..We therefore studied how glycemic control has been affected by using insulin lispro in clinical practice over 5 years in 14 hospitals in Sweden...
  3. ncbi request reprint Changes in HbA1c and frequency of measuring HbA1c and adjusting glucose-lowering medications in the 10 years following diagnosis of type 2 diabetes: a population-based study in the UK
    Marcus Lind
    Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Diabetologia 57:1586-94. 2014
    ..The aim of this work was to study levels of HbA1c and patterns of adjusting glucose-lowering drugs in patients with impaired glycaemic control over 10 years after diagnosis of type 2 diabetes...
  4. doi request reprint Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study
    M Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Diabetologia 56:2601-8. 2013
    ..The aim of this study was to determine the contemporary rate ratio of mortality and changes over time in individuals with vs without diabetes...
  5. doi request reprint Incretin therapy and its effect on body weight in patients with diabetes
    Marcus Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Prim Care Diabetes 6:187-91. 2012
    ....
  6. doi request reprint The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes
    M Lind
    Department of Medicine, Uddevalla Hospital, 451 80 Uddevalla, Sweden
    Diabetologia 55:2946-53. 2012
    ..The aim of this study was to examine the relationship between glycaemic control and hospitalisation for heart failure in patients with type 2 diabetes...
  7. doi request reprint The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes
    Marcus Lind
    Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Prim Care Diabetes 6:53-9. 2012
    ..To elucidate methodological questions in assessing the relationship between insulin treatment and cancer, since the risk of tumour growth generally increases with longer exposure time and higher dose of a growth promoting substance...
  8. doi request reprint Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
    Marcus Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Prim Care Diabetes 6:41-6. 2012
    ..To evaluate the effects of adding glucagon-like peptide-1 (GLP-1) analogue therapy to insulin on glycated hemoglobin (HbA1c), weight, insulin dosage, treatment satisfaction, and risk of hypoglycaemia...
  9. pmc The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables
    Marcus Lind
    Department of Medicine, Uddevalla Hospital, Uddevalla, Sweden
    PLoS ONE 4:e4412. 2009
    ..We studied whether the updated mean HbA1c underestimated the risk of diabetic complications...
  10. doi request reprint The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects
    M Lind
    Department of Medicine, NU Hospital Organization, SE 451 80 Uddevalla, Sweden
    Diabetologia 53:1093-8. 2010
    ..We determined the shape of the metabolic memory of HbA1c and its contribution to retinopathy, as well as the importance of reducing HbA1c to prevent progression of retinopathy...
  11. doi request reprint Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study
    Marcus Lind
    Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Lancet 378:140-6. 2011
    ..We aimed to assess this association in a large cohort of patients with type 1 diabetes identified from the Swedish national diabetes registry...
  12. pmc Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practice
    Jenny Anderson
    Department of Medicine, NU Hospital Organization, Trollhattan, Sweden
    J Diabetes Sci Technol 5:1472-9. 2011
    ..The effects of CGM on glycemic control in clinical practice in relation to indication and duration of use has not been completely studied...
  13. pmc Relationship between overweight and obesity with hospitalization for heart failure in 20,985 patients with type 1 diabetes: a population-based study from the Swedish National Diabetes Registry
    Daniel Vestberg
    Department of Medicine, NU Hospital Organization, Sweden
    Diabetes Care 36:2857-61. 2013
    ..To investigate the potential relationship between overweight, obesity, and severe obesity and the risk of hospitalization for heart failure (HF) in patients with type 1 diabetes...
  14. doi request reprint Insulin pump-long-term effects on glycemic control: an observational study at 10 diabetes clinics in Sweden
    Britt Marie Carlsson
    Department of Medicine, SÄS Hospital Organization, Skene, Sweden
    Diabetes Technol Ther 15:302-7. 2013
    ..This study examined long-term effects of continuous subcutaneous insulin infusion (CSII) in clinical practice on glycemic control in patients with type 1 diabetes...
  15. doi request reprint The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial
    Linda G Mellbin
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Eur Heart J 34:374-9. 2013
    ..The present aim was to study the possibility of such a relation in patients with type 2 diabetes (T2DM) and AMI...
  16. doi request reprint Thrombomodulin as a marker for bleeding complications during warfarin treatment
    Marcus Lind
    Department of Medicine, Skellefteå County Hospital, Skellefteå, Sweden
    Arch Intern Med 169:1210-5. 2009
    ..This study aimed to test if thrombomodulin (TM) concentrations were associated with bleeding complications, cardiovascular events, or mortality in long-term anticoagulant-treated patients...